Taysha Gene Therapies Inc (NASDAQ:TSHA)’s traded shares stood at 1.4 million during the last session, with the company’s beta value hitting 0.32. At the close of trading, the stock’s price was $2.45, to imply a decrease of -4.85% or -$0.13 in intraday trading. The TSHA share’s 52-week high remains $3.89, putting it -58.78% down since that peak but still an impressive 79.59% since price per share fell to its 52-week low of $0.50. The company has a valuation of $458.20M, with an average of 2.75 million shares over the past 3 months.

Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information

After registering a -4.85% downside in the last session, Taysha Gene Therapies Inc (TSHA) has traded red over the past five days. The stock hit a weekly high of 3.36, dropping -4.85% in its intraday price action. The 5-day price performance for the stock is -21.97%, and 15.02% over 30 days. With these gigs, the year-to-date price performance is 38.42%.

Taysha Gene Therapies Inc (TSHA) estimates and forecasts

Looking at statistics comparing Taysha Gene Therapies Inc share performance against respective industry, we note that the company has outperformed competitors. Taysha Gene Therapies Inc (TSHA) shares are 9.38% up over the last 6 months, with its year-to-date growth rate higher than industry average at 59.38% against 21.60%.

TSHA Dividends

Taysha Gene Therapies Inc has its next earnings report out in May. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Taysha Gene Therapies Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.